ORG-37684: Difference between revisions

{{drugbox | verifiedrevid = 405763311

|

| IUPAC_name = (3S)-3-[(2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy]pyrrolidine

| image = Org37684_structure.png

| width = 240

| CAS_number =

| ATC_prefix =

| ATC_suffix =

| PubChem = 9794656

| IUPHAR_ligand = 171

| C = 14 | H = 19 | N = 1 | O = 2

| molecular_weight = 233.305 g/mol

| smiles = COc1ccc2CCCc2c1OC3CNCC3

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_category =

| routes_of_administration =

'''ORG-37,684''' is a [[drug]] developed by [[Organon International|Organon]], which acts as a [[potency_(pharmacology)|potent]] and [[functional_selectivity|selective]] [[agonist]] for the [[5-HT2 receptor|5-HT₂]] [[receptor (biochemistry)|receptor]] family, with highest [[affinity_(pharmacology)|affinity]] at [[5-HT2C receptor|5-HT_2C]] and lowest at [[5-HT2B receptor|5-HT_2B]] subtypes.<ref>{{cite doi|10.1081/SCC-100104420}}</ref><ref>Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. ''Naunyn Schmiedebergs Archives of Pharmacology''. 2004;370:114-123. {{DOI|10.1007/s00210-004-0951-4}} PMID 15322733</ref> It has [[anorectic]] effects in animal studies and has been researched as a potential [[weight loss]] drug for use in humans.<ref>Schreiber R, De Vry J. Role of 5-hT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. ''Progress in Neuropsychopharmacology and Biological Psychiatry''. 2002 Apr;26(3):441-9. PMID 11999893</ref>

==See also==

* [[Org 12,962]]

{{Anorectics}}

{{Serotonergics}}